Kangstem Biotech

KOR | ENG

주메뉴

Company
- Company
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- About Us
- Kangstem Biotech
- Global R&D Center
- Stem Cell GMP Center
- Welcome Message
- Vision & Mission
- History
- Location
Business
- Business
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- Stem Cell Therapy
- FURESTEM-OA Kit Inj.
- FURESTEM-AD® Inj.
- FURESTEM-RA® Inj.
- Advanced Regenerative Medicine
- Organoid
- Organoid
- Skin Organoid
- Islet Organoid
- CDMO Business
- CDMO
- JUVENTAS
- Stem Cell Culture Business
- Health&Beauty Business
R & D
- R & D
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- Core Technology
- Umbilical Cord Blood Stem Cell
- High-Compact Technology Strategy
- R&D Achievements
Investors
- Investors
  
  Kangstem Biotech is
  engaged in various fields
  of bio-innovation.
- Notice
- PR
- Press Release
- PR Resource Center

Core Technology

Umbilical Cord Blood Stem Cell

Kangstem Biotech is developing stem cell therapeutic products for patients suffering from rare and incurable diseases using umbilical cord blood-derived stem cells.

Umbilical
Cord Blood

Next-generation therapeutic innovation derived from the youngest cells

Umbilical cord blood–derived stem cells are among the healthiest and most primitive cells, obtained from the umbilical cord and placenta that connect the mother and fetus, and possess high potential for immunomodulatory and regenerative therapies. Kangstem Biotech Co., Ltd uses only umbilical cord blood collected from natural deliveries at 36 weeks of gestation or later, ensuring uniform quality as well as ethical and non-invasive cell procurement. Based on this approach, the company is developing next-generation regenerative medicine therapies for patients with rare and intractable diseases.

Cord Blood-Derived Stem Cell Isolation Technology and Mass Medium Technology

As the cord blood has a very small amount of existed mesoderm stem cells different from adipose or marrow, it is necessary to have a culture technology to identify the stem cells for isolation and a level for the commercialization of isolated stem cells. Kangstem Biotech has received the support of cord blood stem cell program that is supported by the Seoul City and developed the isolation technology of cord blood-derived stem cells and the mass culturing technology of cord blood-derived stem cells.

Purity

With the original technology of Kangstem Biotech, stem cells with over 95% purity are isolated and cultured, which have the excellent immune control ability, multi-conversion ability and proliferation ability.

Isolation Success Rate

The isolation of stem cells is possible for the cord bloods of more than eight people from the cord bloods obtained from the embryos of ten people with a high rate (80% & higher)

Possible Isolation Time